Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 51407-935

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 51407-935). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000 Tablets (Sacubitrilvalsartan 24 26 mg)

This text provides information about a medication containing sacubitril and valsartan in each film-coated tablet. It mentions the dosage details should be obtained from the prescribing information and provides storage instructions such as maintaining at 25°C with excursions permitted within a certain temperature range. The text also alerts about protecting the medication from moisture and keeping it out of the reach of children. Additionally, it lists the marketer as GSMS, Incorporated in Camarillo, CA, USA. It specifies the quantity of tablets as 1000 and includes the NDC code for reference.*

FDA Label Image

1000 Tablets (Sacubitrilvalsartan 49 51 mg1)

Each film-coated tablet contains 49 mg of sacubitril and 51 mg of valsartan. The usual dosage should be followed as per prescribing information. Store at 25°C (77°F) with excursions permitted to 15° to 30°C (59° to 86°F). It is important to protect the tablets from moisture and keep them out of the reach of children. The product is marketed by GSMS, Incorporated, based in Camarillo, CA 93012, USA. The NDC number is 51407-936-10 for Sacubitril and Valsartan Tablets, 49 mg/51 mg. This package contains 1000 tablets and is prescription-only.*

FDA Label Image

Figure 7 (Sacubitrilvalsartan 7 Figure)

This text seems to be referring to two different studies: PARADIGM-HF and PARAGON-HF, comparing the efficacy of sacubitril and valsartan versus enalapril and sacubitril and valsartan versus valsartan in treating heart failure. It also mentions measuring the left ventricular ejection fraction at screening.*

FDA Label Image

1000 Tablets (Sacubitrilvalsartan 97 103 mg 1)

Each film-coated tablet contains 97 mg of sacubitril and 103 mg of valsartan. The usual dosage should be referred to the prescribing information. Store the tablets at 25°C (77°F), with excursions allowed to 15° to 30°C (59°F to 86°F) following USP Controlled Room Temperature guidelines. Ensure protection from moisture and keep all drugs out of the reach of children. Marketed by GSMS, Incorporated in Camarillo, CA 93012, USA. NDC 51407-937-10. This medication is available in the form of Sacubitril and Valsartan Tablets under the brand name CYRCTALER T. Rx only with a pack containing 1000 Tablets.*

FDA Label Image

Sacubitrilvalsartan-fig-2 (Sacubitrilvalsartan Fig 2)

FDA Label Image

Figure 1 (Sacubitrilvalsartan Fig1)

FDA Label Image

Figure 3 (Sacubitrilvalsartan Fig3)

This is not available.*

FDA Label Image

Figure 4 (Sacubitrilvalsartan Fig4)

This is a data table showing the breakdown of various characteristics and parameters related to heart failure patients, including age, gender, weight, race, region, NYHA class, GFR, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension, prior medication use, hospitalizations for heart failure, time since diagnosis, cause of heart failure, and usage of specific heart failure medications like Sacubitril and Valsartan as well as Enalapril. It also includes percentages related to these categories and the comparison of efficacy between Sacubitril and Valsartan vs. Enalapril using Hazard Ratios.*

FDA Label Image

Figure 6 (Sacubitrilvalsartan Figur6)

FDA Label Image

Figure 5 (Sacubitrilvalsartan Figure5)

This is a data table showing the number of total heart failure hospitalizations and cardiovascular deaths in the PARAGONHF study over a period of time after the patients were randomized to receive Sacubitril and Valsartan. The table includes information for 50 patients over 140 days.*

FDA Label Image

Structure (Sacubitrilvalsartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.